{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:38:17Z","timestamp":1789609097351,"version":"build-2803163510"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Scientific Research Project of Sichuan Health Committee","award":["NO. 19PJ305"],"award-info":[{"award-number":["NO. 19PJ305"]}]},{"DOI":"10.13039\/100012542","name":"Science and Technology Project of Sichuan","doi-asserted-by":"crossref","award":["No. 2019YFS0105"],"award-info":[{"award-number":["No. 2019YFS0105"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Blood derivatives therapy is a conventional clinical treatment, while the treatment for Alzheimer\u2019s disease (AD) is relatively novel. To provide clinical references for treating AD, this meta-analysis was performed to evaluate the efficacy and safety of blood derivatives therapy on the patients with AD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic articles search was performed for eligible studies published up to December 6, 2021 through the PubMed, Embase, Cochrane library,<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>, Chinese National Knowledge Infrastructure database, and Wanfang databases. The included articles were screened by using rigorous inclusion and exclusion criteria. Study selection and data-extraction were performed by two authors independently. Random effects model or fixed effects model was used. Quality of studies and risk of bias were evaluated according to the Cochrane risk of bias tool. All analyses were conducted using Review Manager 5.4. The study was designed and conducted according to the Preferring Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of three plasma administrations (two plasma exchange and one young plasma infusion) and five intravenous immunoglobulin (IVIG) randomized controlled trials with a sample size of 1148 subjects diagnosed with AD were included. There was no significant difference in cognitive improvement and all-cause discontinuation between intervention and placebo groups (RR 1.10, 95% CI 0.79\u20131.54). And Intervention groups showed not a statistically significant improvement in cognition of included subjects measured by the ADAS-Cog (MD 0.36, 95% CI 0.87\u20131.59), ADCS-ADL (MD \u22121.34, 95% CI \u2212 5.01\u20132.32) and NPI (MD 2.20, 95% CI 0.07\u20134.32) score compared to the control groups. IVIG is well tolerated for AD patients even under the maximum dose (0.4 g\/kg), but it is inferior to placebo in Neuropsychiatric Inventory scale in AD patients (MD 2.19, 95% CI 0.02\u20134.37).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The benefits of blood derivatives therapy for AD are limited. It is necessary to perform well-designed randomized controlled trials with large sample sizes focusing on the appropriate blood derivatives for the specific AD sub-populations in the future.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p>PROSPERO CRD42021233886<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13643-022-02115-y","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T07:25:44Z","timestamp":1669706744000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and safety of blood derivatives therapy in Alzheimer\u2019s disease: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3261-7385","authenticated-orcid":false,"given":"Zhangcheng","family":"Fei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renjun","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongsheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"issue":"9","key":"2115_CR1","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1093\/brain\/awv191","volume":"138","author":"R Ossenkoppele","year":"2015","unstructured":"Ossenkoppele R, Pijnenburg YA, Perry DC, Cohn-Sheehy BI, Scheltens NM, Vogel JW, et al. The behavioural\/dysexecutive variant of Alzheimer\u2019s disease: clinical, neuroimaging and pathological features. Brain. 2015;138(9):2732\u201349.","journal-title":"Brain"},{"key":"2115_CR2","doi-asserted-by":"crossref","unstructured":"Alzheimers Association. 2020 Alzheimer's disease facts and figures. Alzheimers Dement. 2020;16(3):391\u2013460.","DOI":"10.1002\/alz.12068"},{"issue":"2","key":"2115_CR3","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","volume":"179","author":"JM Long","year":"2019","unstructured":"Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179(2):312\u201339.","journal-title":"Cell"},{"issue":"14","key":"2115_CR4","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.2174\/1567205017666200102151731","volume":"16","author":"H Cao","year":"2019","unstructured":"Cao H, Du X, Zeng R, Lv Z, Ye S, Jiang P, et al. Effect of different A\u03b2 aggregates as antigen on the measure of naturally occurring autoantibodies against amyloid-\u03b240\/42 in IVIG. Curr Alzheimer Res. 2019;16(14):1290\u20139.","journal-title":"Curr Alzheimer Res"},{"issue":"3","key":"2115_CR5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","volume":"17","author":"F Leng","year":"2021","unstructured":"Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol. 2021;17(3):157\u201372.","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"2115_CR6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.neuron.2020.10.008","volume":"109","author":"Y Chen","year":"2021","unstructured":"Chen Y, Strickland MR, Soranno A, Holtzman DM. Apolipoprotein E: Structural insights and links to alzheimer disease pathogenesis. Neuron. 2021;109(2):205\u201321.","journal-title":"Neuron"},{"issue":"8","key":"2115_CR7","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.biopsych.2020.02.001","volume":"89","author":"H Hampel","year":"2021","unstructured":"Hampel H, Vassar R, De Strooper B, Hardy J, Willem M, Singh N, et al. The \u03b2-Secretase BACE1 in Alzheimer's Disease. Biol Psychiatry. 2021;89(8):745\u201356.","journal-title":"Biol Psychiatry"},{"key":"2115_CR8","doi-asserted-by":"crossref","first-page":"101208","DOI":"10.1016\/j.arr.2020.101208","volume":"65","author":"A John","year":"2021","unstructured":"John A, Reddy PH. Synaptic basis of Alzheimer's disease: Focus on synaptic amyloid beta, P-tau and mitochondria. Ageing Res Rev. 2021;65:101208.","journal-title":"Ageing Res Rev"},{"key":"2115_CR9","doi-asserted-by":"crossref","first-page":"101212","DOI":"10.1016\/j.arr.2020.101212","volume":"65","author":"S Ayton","year":"2021","unstructured":"Ayton S, Bush AI. \u03b2-amyloid: The known unknowns. Ageing Res Rev. 2021;65:101212.","journal-title":"Ageing Res Rev"},{"issue":"1","key":"2115_CR10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/0363546520909397","volume":"49","author":"JW Belk","year":"2021","unstructured":"Belk JW, Kraeutler MJ, Houck DA, Goodrich JA, Dragoo JL, Mccarty EC. Platelet-rich plasma versus hyaluronic acid for knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Am J Sports Med. 2021;49(1):249\u201360.","journal-title":"Am J Sports Med"},{"issue":"3","key":"2115_CR11","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/anae.15181","volume":"76","author":"G Erdoes","year":"2021","unstructured":"Erdoes G, Koster A, Ortmann E, Meesters MI, Bolliger D, Baryshnikova E, et al. A European consensus statement on the use of four-factor prothrombin complex concentrate for cardiac and non-cardiac surgical patients. Anaesthesia. 2021;76(3):381\u201392.","journal-title":"Anaesthesia"},{"issue":"10","key":"2115_CR12","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/alz.12137","volume":"16","author":"B Merc\u00e8","year":"2020","unstructured":"Merc\u00e8 B, L\u00f3pez OL, Javier O, Laura N, Michael P, Mar\u00eda P, et al. A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study. Alzheimers Dement. 2020;16(10):1412\u201325.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2115_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11357-020-00297-8","volume":"43","author":"M Mehdipour","year":"2021","unstructured":"Mehdipour M, Mehdipour T, Skinner CM, Wong N, Liu C, Chen C-C, et al. Plasma dilution improves cognition and attenuates neuroinflammation in old mice. GeroScience. 2021;43(1):1\u201318.","journal-title":"GeroScience"},{"issue":"7027","key":"2115_CR14","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nature03260","volume":"433","author":"IM Conboy","year":"2005","unstructured":"Conboy IM, Conboy MJ, Wagers AJ, Girma ER, Weissman IL, Rando TAJN. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature. 2005;433(7027):760\u20134.","journal-title":"Nature"},{"issue":"4","key":"2115_CR15","first-page":"e13","volume":"73","author":"LA Henderson","year":"2021","unstructured":"Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2. Arthritis Rheum. 2021;73(4):e13\u201329.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2115_CR16","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/WCO.0000000000000909","volume":"34","author":"CG Bien","year":"2021","unstructured":"Bien CG. Management of autoimmune encephalitis. Curr Opin Neurol. 2021;34(2):166\u201371.","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"2115_CR17","doi-asserted-by":"crossref","first-page":"78","DOI":"10.2500\/aap.2021.42.200113","volume":"42","author":"M Dilley","year":"2021","unstructured":"Dilley M, Wangberg H, Noone J, Geng B. Primary immunodeficiency diseases treated with immunoglobulin and associated comorbidities. Allergy Asthma Proc. 2021;42(1):78\u201386.","journal-title":"Allergy Asthma Proc"},{"issue":"6","key":"2115_CR18","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.autrev.2008.04.011","volume":"7","author":"J Vani","year":"2008","unstructured":"Vani J, Elluru S, Negi V-S, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, et al. Role of natural antibodies in immune homeostasis: IVIg perspective. Autoimmun Rev. 2008;7(6):440\u20134.","journal-title":"Autoimmun Rev"},{"issue":"51","key":"2115_CR19","doi-asserted-by":"crossref","first-page":"32691","DOI":"10.1073\/pnas.1908658117","volume":"117","author":"S Dubey","year":"2020","unstructured":"Dubey S, Heinen S, Krantic S, Mclaurin J, Branch DR, Hynynen K, et al. Clinically approved IVIg delivered to the hippocampus with focused ultrasound promotes neurogenesis in a model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2020;117(51):32691\u2013700.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2115_CR20","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jneuroim.2017.09.011","volume":"313","author":"M Krestova","year":"2017","unstructured":"Krestova M, Hromadkova L, Bilkova Z, Bartos A, Ricny J. Characterization of isolated tau-reactive antibodies from the IVIG product, plasma of patients with Alzheimer's disease and cognitively normal individuals. J Neuroimmunol. 2017;313:16\u201324.","journal-title":"J Neuroimmunol"},{"issue":"1","key":"2115_CR21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s13311-015-0391-5","volume":"13","author":"JD L\u00fcnemann","year":"2016","unstructured":"L\u00fcnemann JD, Quast I, Dalakas MCJN. Efficacy of intravenous immunoglobulin in neurological diseases. Neurotherapeutics. 2016;13(1):34\u201346.","journal-title":"Neurotherapeutics"},{"key":"2115_CR22","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3389\/fneur.2020.00459","volume":"11","author":"DA Loeffler","year":"2020","unstructured":"Loeffler DA. AMBAR, an Encouraging Alzheimer's trial that raises questions. Front Neurol. 2020;11:459.","journal-title":"Front Neurol"},{"issue":"18","key":"2115_CR23","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1212\/WNL.0000000000003904","volume":"88","author":"NR Relkin","year":"2017","unstructured":"Relkin NR, Thomas RG, Rissman RA, Brewer JB, Rafii MS, Van Dyck CH, et al. A phase 3 trial of IV immunoglobulin for Alzheimer disease. Neurology. 2017;88(18):1768\u201375.","journal-title":"Neurology"},{"key":"2115_CR24","unstructured":"Nct. Phase 3 IGIV, 10% in Alzheimer\u2019s Disease. https:\/\/clinicaltrials.gov\/show\/NCT01524887, 2012;"},{"issue":"7","key":"2115_CR25","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Medicine PGJP. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med"},{"issue":"2","key":"2115_CR26","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3233\/JAD-170991","volume":"63","author":"JK Kueper","year":"2018","unstructured":"Kueper JK, Speechley M, Montero-Odasso M. The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): Modifications and Responsiveness in Pre-Dementia Populations. A Narrative Review. J Alzheimers Dis. 2018;63(2):423\u201344.","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"2115_CR27","doi-asserted-by":"crossref","first-page":"e0121478","DOI":"10.1371\/journal.pone.0121478","volume":"10","author":"VA Holthoff","year":"2015","unstructured":"Holthoff VA, Marschner K, Scharf M, Steding J, Meyer S, Koch R, et al. Effects of physical activity training in patients with Alzheimer's dementia: results of a pilot RCT study. PLoS One. 2015;10(4):e0121478.","journal-title":"PLoS One"},{"issue":"8","key":"2115_CR28","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/gps.3904","volume":"28","author":"M Canevelli","year":"2013","unstructured":"Canevelli M, Adali N, Voisin T, Soto ME, Bruno G, Cesari M, et al. Behavioral and psychological subsyndromes in Alzheimer's disease using the Neuropsychiatric Inventory. Int J Geriatr Psychiatry. 2013;28(8):795\u2013803.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"4 Suppl 3","key":"2115_CR29","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1097\/01.wad.0000213878.47924.44","volume":"20","author":"LS Schneider","year":"2006","unstructured":"Schneider LS, Clark CM, Doody R, Ferris SH, Morris JC, Raman R, et al. ADCS Prevention Instrument Project: ADCS-clinicians' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions. Alzheimer Dis Assoc Disord. 2006;20(4 Suppl 3):S124\u201338.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"1","key":"2115_CR30","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jalz.2019.05.013","volume":"16","author":"T Miyagawa","year":"2020","unstructured":"Miyagawa T, Brushaber D, Syrjanen J, Kremers W, Fields J, Forsberg LK, et al. Use of the CDR\u00ae plus NACC FTLD in mild FTLD: Data from the ARTFL\/LEFFTDS consortium. Alzheimers Dement. 2020;16(1):79\u201390.","journal-title":"Alzheimers Dement"},{"key":"2115_CR31","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"issue":"1","key":"2115_CR32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/jamaneurol.2018.3288","volume":"76","author":"SJ Sha","year":"2019","unstructured":"Sha SJ, Deutsch GK, Tian L, Richardson K, Coburn M, Gaudioso JL, et al. Safety, tolerability, and feasibility of young plasma infusion in the plasma for Alzheimer symptom amelioration study: a randomized clinical trial. JAMA Neurol. 2019;76(1):35\u201340.","journal-title":"JAMA Neurol"},{"key":"2115_CR33","unstructured":"Nct. Efficacy and safety of plasma exchange with 5% albumin in beta-amyloid peptide clearance in cerebral spinal fluid. https:\/\/clinicaltrials.gov\/show\/NCT00742417, 2017;"},{"issue":"2","key":"2115_CR34","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/jnnp-2015-311486","volume":"88","author":"S Kile","year":"2017","unstructured":"Kile S, Au W, Parise C, Rose K, Donnel T, Hankins A, et al. IVIG treatment of mild cognitive impairment due to Alzheimer's disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia. J Neurol Neurosurg Psychiatry. 2017;88(2):106\u201312.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"2115_CR35","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1474-4422(13)70014-0","volume":"12","author":"R Dodel","year":"2013","unstructured":"Dodel R, Rominger A, Bartenstein P, Barkhof F, Blennow K, F\u00f6rster S, et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol. 2013;12(3):233\u201343.","journal-title":"Lancet Neurol"},{"issue":"3","key":"2115_CR36","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/psyg.12055","volume":"14","author":"H Arai","year":"2014","unstructured":"Arai H, Ichimiya Y, Shibata N, Nakajima T, Sudoh S, Tokuda T, et al. Safety and tolerability of immune globulin intravenous (human), 10% solution in Japanese subjects with mild to moderate Alzheimer's disease. Psychogeriatrics. 2014;14(3):165\u201374.","journal-title":"Psychogeriatrics"},{"issue":"3","key":"2115_CR37","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s13311-019-00746-z","volume":"16","author":"V Kheifets","year":"2019","unstructured":"Kheifets V, Braithwaite SP. Plasma-based strategies for therapeutic modulation of brain aging. Neurotherapeutics. 2019;16(3):675\u201384.","journal-title":"Neurotherapeutics"},{"issue":"3","key":"2115_CR38","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/archneurol.2008.596","volume":"66","author":"T Tapiola","year":"2009","unstructured":"Tapiola T, Alafuzoff I, Herukka S-K, Parkkinen L, Hartikainen P, Soininen H, et al. Cerebrospinal fluid \u03b2-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66(3):382\u20139.","journal-title":"Arch Neurol"},{"issue":"1","key":"2115_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging\u2013Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012;8(1):1\u201313.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2115_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms13363","volume":"7","author":"J Rebo","year":"2016","unstructured":"Rebo J, Mehdipour M, Gathwala R, Causey K, Liu Y, Conboy MJ, et al. A single heterochronic blood exchange reveals rapid inhibition of multiple tissues by old blood. Nat Commun. 2016;7(1):1\u201311.","journal-title":"Nat Commun"},{"issue":"8","key":"2115_CR41","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nm.3898","volume":"21","author":"LK Smith","year":"2015","unstructured":"Smith LK, He Y, Park J-S, Bieri G, Snethlage CE, Lin K, et al. \u03b22-microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesis. Nat Med. 2015;21(8):932\u20137.","journal-title":"Nat Med"},{"issue":"7362","key":"2115_CR42","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature10357","volume":"477","author":"SA Villeda","year":"2011","unstructured":"Villeda SA, Luo J, Mosher KI, Zou B, Britschgi M, Bieri G, et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature. 2011;477(7362):90\u20134.","journal-title":"Nature"},{"issue":"22","key":"2115_CR43","first-page":"23394","volume":"12","author":"JS Kang","year":"2020","unstructured":"Kang JS, Yang YRJA. Circulating plasma factors involved in rejuvenation. Aging (Albany NY). 2020;12(22):23394.","journal-title":"Aging (Albany NY)"},{"key":"2115_CR44","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.dadm.2016.05.004","volume":"3","author":"BM Bettcher","year":"2016","unstructured":"Bettcher BM, Fitch R, Wynn MJ, Lalli MA, Elofson J, Jastrzab L, et al. MCP-1 and eotaxin-1 selectively and negatively associate with memory in MCI and Alzheimer's disease dementia phenotypes. Alzheimers Dement (Amst). 2016;3:91\u20137.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"12","key":"2115_CR45","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1002\/glia.22892","volume":"63","author":"B Parajuli","year":"2015","unstructured":"Parajuli B, Horiuchi H, Mizuno T, Takeuchi H, Suzumura AJG. CCL11 enhances excitotoxic neuronal death by producing reactive oxygen species in microglia. Glia. 2015;63(12):2274\u201384.","journal-title":"Glia"},{"issue":"25","key":"2115_CR46","doi-asserted-by":"crossref","first-page":"12524","DOI":"10.1073\/pnas.1902672116","volume":"116","author":"KJ Gan","year":"2019","unstructured":"Gan KJ, S\u00fcdhof TC. Specific factors in blood from young but not old mice directly promote synapse formation and NMDA-receptor recruitment. Proc Natl Acad Sci U S A. 2019;116(25):12524\u201333.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7651","key":"2115_CR47","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nature22067","volume":"544","author":"JM Castellano","year":"2017","unstructured":"Castellano JM, Mosher KI, Abbey RJ, Mcbride AA, James ML, Berdnik D, et al. Human umbilical cord plasma proteins revitalize hippocampal function in aged mice. Nature. 2017;544(7651):488\u201392.","journal-title":"Nature"},{"issue":"1","key":"2115_CR48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-2094-7-90","volume":"7","author":"J Magga","year":"2010","unstructured":"Magga J, Puli L, Pihlaja R, Kanninen K, Neulamaa S, Malm T, et al. Human intravenous immunoglobulin provides protection against A\u03b2 toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J Neuroinflammation. 2010;7(1):1\u201315.","journal-title":"J Neuroinflammation"},{"issue":"9","key":"2115_CR49","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1017\/S1041610220000496","volume":"32","author":"JC Monfort","year":"2020","unstructured":"Monfort JC, Lezy AM, Papin A, Tezenas Du Montcel S. Psychogeriatric Inventory of Disconcerting Symptoms and Syndromes (PGI-DSS): validity and reliability of a new brief scale compared to the Neuropsychiatric Inventory for Nursing Homes (NPI-NH). Int Psychogeriatr. 2020;32(9):1085\u201395.","journal-title":"Int Psychogeriatr"},{"key":"2115_CR50","doi-asserted-by":"crossref","first-page":"100948","DOI":"10.1016\/j.arr.2019.100948","volume":"55","author":"F Panza","year":"2019","unstructured":"Panza F, Lozupone M, Bellomo A, Imbimbo BPJArr. Do anti-amyloid-\u03b2 drugs affect neuropsychiatric status in Alzheimer\u2019s disease patients? Ageing Res Rev. 2019;55:100948.","journal-title":"Ageing Res Rev"},{"key":"2115_CR51","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.brainresbull.2014.09.003","volume":"108","author":"S Holmgren","year":"2014","unstructured":"Holmgren S, Hjorth E, Schultzberg M, L\u00e4rks\u00e4ter M, Frenkel D, Tysen-B\u00e4ckstr\u00f6m AC, et al. Neuropsychiatric symptoms in dementia\u2014a role for neuroinflammation? Brain Res Bull. 2014;108:88\u201393.","journal-title":"Brain Res Bull"},{"issue":"8","key":"2115_CR52","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.4049\/jimmunol.179.8.5571","volume":"179","author":"A Kessel","year":"2007","unstructured":"Kessel A, Ammuri H, Peri R, Pavlotzky ER, Blank M, Shoenfeld Y, et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol. 2007;179(8):5571\u20135.","journal-title":"J Immunol"},{"issue":"6","key":"2115_CR53","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1189\/jlb.3VMA0315-078R","volume":"98","author":"LK Kozicky","year":"2015","unstructured":"Kozicky LK, Zhao ZY, Menzies SC, Fidanza M, Reid GS, Wilhelmsen K, et al. Intravenous immunoglobulin skews macrophages to an anti-inflammatory, IL-10-producing activation state. J Leukoc Biol. 2015;98(6):983\u201394.","journal-title":"J Leukoc Biol"},{"issue":"1","key":"2115_CR54","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1053\/j.ajkd.2009.06.013","volume":"55","author":"CC Welles","year":"2010","unstructured":"Welles CC, Tambra S, Lafayette RA. Hemoglobinuria and acute kidney injury requiring hemodialysis following intravenous immunoglobulin infusion. Am J Kidney Dis. 2010;55(1):148\u201351.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"2115_CR55","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.autrev.2006.08.011","volume":"6","author":"U Katz","year":"2007","unstructured":"Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev. 2007;6(4):257\u20139.","journal-title":"Autoimmun Rev"},{"issue":"15","key":"2115_CR56","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.1523\/JNEUROSCI.4401-10.2011","volume":"31","author":"R Dodel","year":"2011","unstructured":"Dodel R, Balakrishnan K, Keyvani K, Deuster O, Neff F, Andrei-Selmer LC, et al. Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease. J Neurosci. 2011;31(15):5847\u201354.","journal-title":"J Neurosci"},{"key":"2115_CR57","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1742-2094-7-90","volume":"7","author":"J Magga","year":"2010","unstructured":"Magga J, Puli L, Pihlaja R, Kanninen K, Neulamaa S, Malm T, et al. Human intravenous immunoglobulin provides protection against A\u03b2 toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J Neuroinflammation. 2010;7:90.","journal-title":"J Neuroinflammation"},{"issue":"Pt 9","key":"2115_CR58","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/brain\/awg191","volume":"126","author":"Y Du","year":"2003","unstructured":"Du Y, Wei X, Dodel R, Sommer N, Hampel H, Gao F, et al. Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain. 2003;126(Pt 9):1935\u20139.","journal-title":"Brain"},{"issue":"6","key":"2115_CR59","doi-asserted-by":"crossref","first-page":"e37243","DOI":"10.1371\/journal.pone.0037243","volume":"7","author":"F K\u00e4sermann","year":"2012","unstructured":"K\u00e4sermann F, Boerema DJ, R\u00fcegsegger M, Hofmann A, Wymann S, Zuercher AW, et al. Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation. PLoS One. 2012;7(6):e37243.","journal-title":"PLoS One"},{"issue":"6","key":"2115_CR60","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.febslet.2005.01.039","volume":"579","author":"T Taniguchi","year":"2005","unstructured":"Taniguchi T, Sumida M, Hiraoka S, Tomoo K, Kakehi T, Minoura K, et al. Effects of different anti-tau antibodies on tau fibrillogenesis: RTA-1 and RTA-2 counteract tau aggregation. FEBS Lett. 2005;579(6):1399\u2013404.","journal-title":"FEBS Lett"},{"issue":"2","key":"2115_CR61","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1039\/C6CS00731G","volume":"46","author":"SJ Lee","year":"2017","unstructured":"Lee SJ, Nam E, Lee HJ, Savelieff MG, Lim MH. Towards an understanding of amyloid-\u03b2 oligomers: characterization, toxicity mechanisms, and inhibitors. Chem Soc Rev. 2017;46(2):310\u201323.","journal-title":"Chem Soc Rev"},{"issue":"2","key":"2115_CR62","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1474-4422(19)30480-6","volume":"19","author":"L Schneider","year":"2020","unstructured":"Schneider L. A resurrection of aducanumab for Alzheimer's disease. Lancet Neurol. 2020;19(2):111\u20132.","journal-title":"Lancet Neurol"},{"issue":"1","key":"2115_CR63","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/med.21622","volume":"40","author":"NM Moussa-Pacha","year":"2020","unstructured":"Moussa-Pacha NM, Abdin SM, Omar HA, Alniss H, Al-Tel TH. BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease. Med Res Rev. 2020;40(1):339\u201384.","journal-title":"Med Res Rev"},{"issue":"1","key":"2115_CR64","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13195-020-00622-5","volume":"12","author":"CB Lessard","year":"2020","unstructured":"Lessard CB, Rodriguez E, Ladd TB, Minter LM, Osborne BA, Miele L, et al. \u03b3-Secretase modulators exhibit selectivity for modulation of APP cleavage but inverse \u03b3-secretase modulators do not. Alzheimers Res Ther. 2020;12(1):61.","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"2115_CR65","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cell.2020.11.049","volume":"184","author":"G Yang","year":"2021","unstructured":"Yang G, Zhou R, Guo X, Yan C, Lei J, Shi Y. Structural basis of \u03b3-secretase inhibition and modulation by small molecule drugs. Cell. 2021;184(2):521\u201333.e14.","journal-title":"Cell"},{"issue":"1","key":"2115_CR66","doi-asserted-by":"crossref","first-page":"e12115","DOI":"10.1002\/trc2.12115","volume":"6","author":"J Hannestad","year":"2020","unstructured":"Hannestad J, Koborsi K, Klutzaritz V, Chao W, Ray R, P\u00e1ez A, et al. Safety and tolerability of GRF6019 in mild-to-moderate Alzheimer's disease dementia. Alzheimers Dement (N Y). 2020;6(1):e12115.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"4","key":"2115_CR67","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.3233\/JAD-210011","volume":"81","author":"J Hannestad","year":"2021","unstructured":"Hannestad J, Duclos T, Chao W, Koborsi K, Klutzaritz V, Beck B, et al. Safety and tolerability of GRF6019 infusions in severe Alzheimer's disease: a phase II double-blind placebo-controlled trial. J Alzheimers Dis. 2021;81(4):1649\u201362.","journal-title":"J Alzheimers Dis"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-022-02115-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-022-02115-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-022-02115-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T03:59:03Z","timestamp":1701489543000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-022-02115-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2115"],"URL":"https:\/\/doi.org\/10.1186\/s13643-022-02115-y","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,29]]},"assertion":[{"value":"8 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This does not involve experiments on human subjects and animal subjects. No conflict of interest exists in the submission of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"256"}}